How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

585 results for

Antithyroid Antibody

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Elevated Antithyroid Peroxidase and Antinuclear Autoantibody Titers in Ménière's Disease Patients: More than a Chance Association? (PubMed)

Elevated Antithyroid Peroxidase and Antinuclear Autoantibody Titers in Ménière's Disease Patients: More than a Chance Association? The aim of this prospective study is to evaluate the possible association between Ménière's disease (MD) and autoantibodies.Fifty-five patients with definite MD (51 unilateral and 4 bilateral) were matched with 55 patients with unilateral vestibular paresis without cochlear involvement and 55 healthy subjects. Blood samples were collected from all study subjects (...) for the determination of serum TSH, free triiodothyronine, free thyroxine, anti-TSH receptor antibody, antithyroperoxidase antibody, antithyroglobulin antibody and of antibodies to non-organ-specific antigens, namely antinuclear antibodies, antibodies to extractable nuclear antigens and antineutrophilic cytoplasmic antibodies.Thirty-three subjects (60%) of the MD group had 1 or more elevated serum autoantibody levels, both organ and non-organ specific; 16 patients (29.1%) with unilateral vestibular paresis had 1

2009 Audiology & Neuro-Otology

82. Urticaria

antithyroid antibodies are associated with lasting duration of chronic urticaria. At least 20% of people with chronic urticaria requiring referral to secondary care are still symptomatic 10 years after first presentation. About 25% of children with chronic spontaneous urticaria are disease-free 3 years after presentation, and 96% are asymptomatic after 7 years. Spontaneous resolution of chronic urticaria usually occurs in up to 50% of people within 1 year and in 80% of people by 5 years. However

2018 NICE Clinical Knowledge Summaries

83. Thyroid function reference values in healthy iodine-sufficient pregnant women and influence of thyroid nodules on thyroid-stimulating hormone and free thyroxine values. (PubMed)

) in the three pregnancy trimesters in iodine-sufficient pregnant women, and to analyze the influence of thyroid nodules on thyroid function during pregnancy.This was a prospective, longitudinal study comprising 400 pregnant women with no history of thyroid disease and no medication influencing thyroid function. TSH, fT4, antithyroglobulin, and antithyroid peroxidase antibodies were measured each trimester by chemiluminescent immunoassays. Urinary iodine concentration was measured in the first trimester when

2019 Thyroid

84. Trimester-specific reference ranges for thyroid hormones in pregnant women. (PubMed)

history of thyroid disease, and consumption of estrogen or antithyroid drugs. Thyroid palpation was performed to exclude the thyroid goiter. Thyroid function and urine iodine were measured by chemiluminescence and arsenic cerium analysis.The trimester-specific reference ranges in Nanjing were as follows: thyroid-stimulating hormone (TSH) 0.02 to 3.78 mIU/L, free thyroxine (FT4) 13.93 to 26.49 pmol/L, total thyroxine (TT4) 103.39 to 319.43 nmol/L in the 1st trimester. TSH 0.47 to 3.89 mIU/L, FT4 12.33 (...) to 19.33 pmol/L, TT4 92.28 to 234.88 nmol/L in the 2nd trimester. TSH 0.55 to 4.91 mIU/L, FT4 11.38 to 19.21 pmol/L, TT4 83.54 to 258.12 nmol/L in the 3rd trimester. According to the TSH reference range recommended by American Thyroid Association (ATA), the prevalence of subclinical hypothyroidism, subclinical hyperthyroidism, hyperthyroidism, hypothyroxinemia, and thyroid peroxidase antibody-positive were 12.42%, 0.50%, 0.99%, 1.61%, and 11.80%, respectively, prevalence according to the trimester

Full Text available with Trip Pro

2019 Medicine

85. Divergent patterns of thyroid-stimulating hormone and other thyroidal parameter levels in relationship with the sex of healthy neonates and infants less than two years old: a longitudinal study. (PubMed)

that were taken into account include antithyroid peroxidase antibody (TPO-Ab) and antithyroglobulin antibody (TG-Ab), total triiodothyronine (T3), and free triiodothyronine (fT3), along with total thyroxine (T4) and free thyroxine (fT4). Methods: Blood samples were taken at 5-day intervals from the day of birth until the 31st day of life, and then every 5th month until 2 years of age. All thyroid parameters were measured by electrochemiluminescence immunoassays. The study took place at the Iaso General

2019 Thyroid

86. Preoperative Thyroid Autoimmune Status and Changes in Thyroid Function and Body Weight After Bariatric Surgery. (PubMed)

recruited 101 patients with morbid obesity (44 men and 57 women) who received bariatric surgery at Zhongshan Hospital, Fudan University. Those who had used thyroid hormone replacement or antithyroid drugs were excluded. General linear models were used to compare the changes in body weight and thyroid function in participants with different thyroid autoimmune statuses.After bariatric surgery, serum-free triiodothyronine (FT3) (4.94 ± 0.73 vs 4.33 ± 0.59 pmol/L, P < 0.001) and thyroid-stimulating hormone (...) (TSH) (3.13 ± 1.59 vs 2.26 ± 1.26 μIU/mL, P < 0.001) were significantly reduced, accompanied by reductions in BMI (42.1 ± 7.6 vs 31.4 ± 6.5 kg/m2, P < 0.001), and estimated basal metabolic rate (2002 ± 398 vs 1700 ± 336 kcal/day, P = 0.001) and an improvement in lipid profiles. Serum thyroperoxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels also decreased significantly from 79.3 and 177.1 IU/mL to 57.8 and 66.0 IU/mL in participants with positive thyroid antibodies (P < 0.05

2019 Obesity Surgery

87. l-selenomethionine supplementation in children and adolescents with autoimmune thyroiditis: A randomized double-blind placebo-controlled clinical trial. (PubMed)

on antithyroid antibody titres in children and adolescents with AT.Seventy-one (71) children and adolescents, with a mean age of 11.3 ± 0.3 years (range 4.5-17.8), diagnosed with AT (antibodies against thyroid peroxidase [anti-TPO] and/or thyroglobulin [anti-Tg] ≥60 IU/mL, euthyroidism or treated hypothyroidism and goitre in thyroid gland ultrasonography) were randomized to receive 200 μg l-selenomethionine or placebo daily for 6 months. Blood samples were drawn for measurement of serum fT4, TSH, anti-TPO

Full Text available with Trip Pro

2019 Journal of clinical pharmacy and therapeutics Controlled trial quality: uncertain

88. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial. (PubMed)

Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial. Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length (...) months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats

2019 Thyroid Controlled trial quality: uncertain

89. Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial. (PubMed)

Long-term Methimazole Therapy in Juvenile Graves' Disease: A Randomized Trial. Recent studies show that long-term (LT) antithyroid drugs reduce relapse of hyperthyroidism in patients with Graves' disease. Our objective was to evaluate the effectiveness and safety of LT methimazole treatment and to compare remission rates in Graves' disease patients after LT and short-term (ST) therapy.In this randomized, parallel group trial, 66 consecutive patients with untreated juvenile Graves (...) of methimazole therapy. Serum free thyroxine, triiodothyronine, thyrotropin, and thyrotropin receptor antibody remained normal, and the required daily dosage of methimazole was gradually decreased from 5.17 ± 1.05 mg at 22 months to 3.5 ± 1.3 mg between 96 and 120 months of treatment (P < .001). Hyperthyroidism was cured in 92% and 88% of LT patients and in 46% and 33% of ST patients, 1 and 4 years after methimazole withdrawal, respectively.LT methimazole treatment of 96 to 120 months is safe and effective

2019 Pediatrics Controlled trial quality: uncertain

90. Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial. (PubMed)

of rituximab (500 mg) and a 12-month course of antithyroid drug (usually carbimazole) can result in a meaningful increase in the proportion of patients in remission at 2 years, the primary endpoint. A single-stage, phase II A'Hern design is used. 27 patients aged 12-20 years with newly presenting Graves' hyperthyroidism will be recruited. Markers of immune function, including lymphocyte numbers and antibody levels (total and specific), will be collected regularly throughout the trial.The trial (...) is more difficult than in older people because the side effects of conventional treatment are more significant in this age group and because the disease tends not to resolve spontaneously in the short to medium term. New immunomodulatory agents are available and the anti-B cell monoclonal antibody rituximab is of particular interest because it targets cells that manufacture the antibodies that stimulate the thyroid gland in Graves'.The trial aims to establish whether the combination of a single dose

Full Text available with Trip Pro

2019 BMJ open Controlled trial quality: uncertain

91. Relationship between Chronic urticaria and autoimmune thyroid disease. (PubMed)

Relationship between Chronic urticaria and autoimmune thyroid disease. Hives is an erythematous and itchy disease that commonly affects the trunk and the organs. Acute urticaria is a common disease and affects about 10%-20% of the population during its lifetime. In patients with chronic urticaria, about 25%-30% of cases, antithyroid peroxidase (TPO) was detected and Hashimoto's disease was diagnosed. This study aimed to evaluate the anti-TPO antibody in patients with chronic urticaria (...) and the effect of treatment of levothyroxine on its recovery. In this study, 72 people with chronic urticaria and positive anti-TPO antibody were randomly divided into two groups. Low-dose antihistamine was administered to both groups, and the first group received levothyroxine at a dose of 50 μg/day. The severity of itching was evaluated according to the visual analog scale before and after therapy. There was no significant difference in the age, sex, thyroid-stimulating hormone (TSH), and anti-TPO between

2019 Journal of advanced pharmaceutical technology & research Controlled trial quality: uncertain

92. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee

Endocrinology (2015) doi:10.1111/cen.12824in 5–10% of the population, being more common in women and increasing with age. 9 It can progress to overt hypothyroidism, par- ticularly if antithyroid antibody positive. 10 In the community, the mostcommon aetiology ischronic autoimmune thyroiditis. 6 There has been a growing controversy about the upper limit of the reference range for serum TSH. 11,12 Reference ranges are derived from a reference population that comprises a large group of subjects who do not have (...) and a signi?cant proportion have subclinical hypothyroidism. Sponta- neous recovery has been described in subjects with subclinical hypothyroidism. It is more likely in those with negative antithy- roid antibodies and serum TSH levels less than 10 mU/l, and within the ?rst 2 years after diagnosis. The higher the serum TSH value, the greater the likelihood of development of overt Table 5. Combination therapy with L-T4 and L-T3 Question Guideline Recommendation Strength/ Evidence Is combination therapy

2015 British Thyroid Association

93. Subclinical hypothyroidism in the infertile female population: a guideline

and 97.5 percentiles of 0.41 and 6.10, respectively, for a disease-free population. However, according to the National Academy of Clinical Biochemistry (NACB), 95% of individ- uals without evidence of thyroid disease have a TSH level 5 mIU/L) (8, 13). Although antithyroid antibodies are not used for the diagnosisofSCH,theyareoftenmeasuredandelevatedlevels havebeenassociatedwithanincreasedlikelihoodofconvert- ingtooverthypothyroidism(14).Normativedataforantithy (...) - roidantibodieshavealsobeenestablishedbytheNHANESIII population (8). While both antithyroglobulin and antithyroid peroxidase antibodies (TPO-Abs) were positive in approxi- mately 10%–12% of the population, only anti-TPO-Abs were associated with thyroid dysfunction and thought to be of clinical signi?cance. A. Nonpregnant women. Despite the ?ndings that TSH levels are skewed in the general population, current evidence does not support treating nonpregnant women for subtle thyroid abnormalities (TSH 2.5mIU/Landlessthantheupper

2015 Society for Assisted Reproductive Technology

94. The Diagnosis and Management of Primary Hypothyroidism

:10.1111/cen.12824in 5–10% of the population, being more common in women and increasing with age. 9 It can progress to overt hypothyroidism, par- ticularly if antithyroid antibody positive. 10 In the community, the mostcommon aetiology ischronic autoimmune thyroiditis. 6 There has been a growing controversy about the upper limit of the reference range for serum TSH. 11,12 Reference ranges are derived from a reference population that comprises a large group of subjects who do not have thyroid disease (...) . Sponta- neous recovery has been described in subjects with subclinical hypothyroidism. It is more likely in those with negative antithy- roid antibodies and serum TSH levels less than 10 mU/l, and within the ?rst 2 years after diagnosis. The higher the serum TSH value, the greater the likelihood of development of overt Table 5. Combination therapy with L-T4 and L-T3 Question Guideline Recommendation Strength/ Evidence Is combination therapy with L-T4 and L-T3 superior to L-T4 monotherapy

2015 British Thyroid Association

95. Atezolizumab (Tecentriq) - Non-Small-Cell Lung Carcinoma or Transitional Cell Carcinoma

Page 4/205 List of abbreviations 1L first-line treatment 2L second-line treatment 2L+ = second-line treatment AC acceptance criterion AE adverse event AESI adverse event of special interest ADCC antibody-dependent cell-mediated cytotoxicity ADE acceptable daily exposure AST aspartate aminotransferase ATA/ATAG anti-therapeutic antibody AUC area under the curve BCG Bacillus Calmette-Guerin BSC best supportive care BOR best overall response CL clearance Cmax maximum observed serum concentration Cmin (...) /153102/2018 Page 10/205 provided to T lymphocytes, thereby allowing their activation and consequently a cytotoxic attack on tumour cells. Checkpoint proteins that are targeted by checkpoint inhibitors in the clinic include cytotoxic T-lymphocyte (CTL)–associated antigen 4 (CTLA4), PD-1, and PD-L1. Immune checkpoint inhibitors, including anti-PD-L1 antibodies, have shown impressive clinical activity as monotherapy in a broad range of tumors, including NSCLC and UC. Atezolizumab targets human PD-L1

2017 European Medicines Agency - EPARs

96. The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria. (PubMed)

days.Medical records of all patients with CSU treated with desloratadine were collected retrospectively during a period from January 2010 to December 2013.Sixty-seven (94.4%) patients had remission of the disease with variable doses of desloratadine. The patients who had CSU concomitant with antithyroid antibodies or high erythrocyte sedimentation rates had a greater tendency not to respond to the standard dose. Once the disease was completely controlled, 67 patients finished the treatment, but 63 (94

2018 International Journal of Dermatology

97. Alterations of global DNA methylation and DNMT expression in T and B lymphocytes from patients with newly diagnosed AITD after treatment: A follow-up study. (PubMed)

patients: 51 with newly diagnosed Graves' disease (GD), 28 with autoimmune hypothyroidism (AIT), 29 with positive thyroid autoantibodies, and 39 matched healthy volunteers. Forty GD patients treated with radioiodine or antithyroid drugs and 28 AIT patients treated with L-thyroxine were followed for three months. Serum free triiodothyronine, free thyroxine, thyrotropin, thyroid peroxidase antibodies, thyroglobulin antibodies, and thyrotropin receptor antibodies were assayed using electrochemiluminescent (...) exhibited differences in their global DNA methylation status or DNMT mRNA levels compared with healthy controls. Antithyroid drugs restored global methylation and DNMT1 expression in both T and B lymphocytes, whereas radioiodine therapy affected only T cells. L-thyroxine replacement did not alter the methylation or DNMT expression levels in lymphocytes. The global methylation levels of B cells were negatively correlated with the serum thyroid peroxidase antibodies in patients with autoimmune thyroid

2018 Thyroid

98. The Oral Microbiota is Associated With Autoimmune Thyroiditis

thyroid function changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months ] Serum thyroid function measured by Immunohistochemistry Other Outcome Measures: Serum thyroid related antibodies changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months ] Serum thyroid related antibodies measured by Immunohistochemistry Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your (...) Action Antithyroid Agents Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2018 Clinical Trials

99. Intestinal Microbiota and Treatment of GD

Secondary Outcome Measures : Serum thyroid function changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal ] Serum thyroid function measured by Immunohistochemistry Other Outcome Measures: Serum thyroid related antibodies changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal ] Serum thyroid related antibodies measured (...) Molecular Mechanisms of Pharmacological Action Antithyroid Agents Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2018 Clinical Trials

100. Fine mapping MHC associations in Graves' disease and its clinical subtypes in Han Chinese. (PubMed)

of the MHC association to GD risk. We further evaluated risk of two clinical subtypes of GD, namely persistent thyroid stimulating hormone receptor antibody -positive (pTRAb+) group and 'non-persistent TRAb positive' (pTRAb-) group after antithyroid drug therapy. We found that HLA-B residues Lys66-Arg69-Val76 could drive pTRAb- GD risk alone, while HLA-DPβ1 position 205, HLA-B position 69 and 199 and HLA-DRβ1 position 28 drive pTRAb+ GD risk. The risk heterogeneity between pTRAb+ and pTRAb- GD might

Full Text available with Trip Pro

2018 Journal of Medical Genetics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>